Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.
Journal: The journal of prevention of Alzheimer's disease
Year: January 12, 2025
Neurologist
4.5
No OPD information available
Dementia
Alzheimer's Disease
CACH Syndrome
Memory Loss
Obsessive-Compulsive Disorder (OCD)
Vascular Dementia
Stephen R. Macfarlane is a male healthcare provider who helps people with memory-related issues like Dementia, Alzheimer's Disease, CACH Syndrome, Memory Loss, Obsessive-Compulsive Disorder (OCD), and Vascular Dementia.
Stephen R. Macfarlane uses special skills and treatments to help patients with memory problems. He listens carefully to their concerns and works with them to find the best solutions for their needs.
Patients trust Stephen R. Macfarlane because he communicates in a friendly and caring way. He takes the time to explain things clearly and makes sure patients feel comfortable and understood.
Stephen R. Macfarlane stays updated with the latest medical knowledge and research to provide the best care for his patients. This helps him offer the most effective treatments and solutions for memory-related issues.
Stephen R. Macfarlane works closely with colleagues and other medical professionals to provide comprehensive care for his patients. He values teamwork and collaboration to ensure the best outcomes for those he helps.
Through his work, Stephen R. Macfarlane has positively impacted many patients' lives by improving their memory and quality of life. His dedication to helping others has made a real difference in the health and well-being of those he cares for.
One of Stephen R. Macfarlane's notable publications is "Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial" published in The Journal of Prevention of Alzheimer's Disease on January 12, 2025.
Stephen R. Macfarlane is also involved in a clinical trial called "Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease," which is in Phase 3 and currently active but not recruiting participants.
Journal: The journal of prevention of Alzheimer's disease
Year: January 12, 2025
Enrollment Status: Active not recruiting
Published: February 27, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Stephen R. Macfarlane is an amazing Neurologist! He really took the time to listen to my concerns and provided thorough explanations. Highly recommend!
I had a great experience with Stephen R. Macfarlane. He is very knowledgeable and caring. I felt comfortable discussing my health issues with him.
Stephen R. Macfarlane is a fantastic Neurologist. He was attentive and compassionate during my consultation. I left feeling confident in his expertise.
I highly recommend Stephen R. Macfarlane as a Neurologist. He was thorough in his examination and treatment plan. Very pleased with the care I received.
Stephen R. Macfarlane is an exceptional Neurologist. He was patient in addressing all my questions and concerns. I felt well taken care of under his guidance.
I had a positive experience with Stephen R. Macfarlane. He was professional and understanding, making me feel at ease throughout my appointment.
Stephen R. Macfarlane is a top-notch Neurologist. He has a great bedside manner and truly cares about his patients' well-being. I'm grateful for his expertise.
I am impressed with Stephen R. Macfarlane's knowledge and dedication as a Neurologist. He provided me with excellent care and support. Highly recommend him!